Strides Pharma's Q1FY27 revenue rose 13% YoY to ₹1,265.4 Cr, led by 17% Ex-US growth.

Strides Pharma Science LimitedSTAR · Filed with the exchange

EBITDA increased 5.4% to ₹229.8 Cr, absorbing ₹13.1 Cr geopolitical costs.

The company unlocked ₹100 Cr from Pivot Path divestment and reduced net debt by ₹11.9 Cr.

No comments yet. Be the first.

More from Strides Pharma Science Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.